DavidPhilipHudesmanMD
Gastroenterology • New York, NYInflammatory Bowel Disease
Associate Professor of Medicine, NYU School of Medicine Co-Director, Inflammatory Bowel Disease Center at NYU Langone Health
Dr. Hudesman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
305 East 33rd Street
New York, NY 10016
Education & Training
Icahn School of Medicine at Mount Sinai/Morningside/WestFellowship, Gastroenterology, 2008 - 2011- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2005 - 2008
Rutgers New Jersey Medical SchoolClass of 2005
Certifications & Licensure
NY State Medical License 2007 - 2026
CT State Medical License 2022 - 2024
FL State Medical License 2022 - 2024
PA State Medical License 2022 - 2024- American Board of Internal Medicine Gastroenterology
Clinical Trials
- Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis Start of enrollment: 2012 Feb 01
- Identify Predictors That Distinguish Between Tofacitinib Responders and Non-responders Based on Genotype and Cellular and Molecular Profiles From Pinch Biopsies, Blood and Stool Samples Start of enrollment: 2018 Dec 04
Publications & Presentations
PubMed
- 7 citationsAlvimopan for the Prevention of Postoperative Ileus in Inflammatory Bowel Disease Patients.Janice Jang, Benjamin Kwok, Hua Zhong, Yuhe Xia, Alexis L. Grucela
Digestive Diseases and Sciences. 2020-04-01 - 9 citationsAssociation of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program.Marla C Dubinsky, Fernando Magro, Flavio Steinwurz, David P Hudesman, Jami A Kinnucan
Inflammatory Bowel Diseases. 2023-01-05 - 157 citationsSerum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease.June-Yong Lee, Jason A Hall, Lina Kroehling, Lin Wu, Tariq Najar
Cell. 2020-01-09
Journal Articles
- Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumLeah Katta, Robert Hirten, Shannon Chang, Dana Lukin, Edward V Loftus, David Faleck, Arun Swaminath, William J Sandborn, Sashidhar Varma Sagi, Sunanda Kane, Prianka Ch..., Nature
- Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumGursimran Kochhar, Justin Hartke, Sashidhar Varma Sagi, Edward V Loftus, Joseph Meserve, Robert Hirten, David Faleck, Shannon Chang, Dana Lukin, Farhad Peerani, Leah K..., Nature
Press Mentions
IBD Drive Time: David Hudesman, MD, on Work Productivity in IBDSeptember 19th, 2024- Ulcerative Colitis: AI Program Shows Promise in Predicting Flare-UpsMarch 7th, 2023
What Is Inflammatory Bowel Disease?November 7th, 2018- Join now to see all
Committees
- Cochair, CCFA Medical Advisory Committee - NYC Chapter
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
